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CLSI

:   Clinical and Laboratory Standards Institute

EUCAST

:   European Union Committee on Antimicrobial Susceptibility Testing

MIC

:   minimal inhibitory concentration

P‐G

:   procaine penicillin with gentamicin sulfate combination

TMPS

:   trimethoprim‐sulfamethoxazole

1. INTRODUCTION {#jvim15685-sec-0006}
===============

Antimicrobial use in veterinary practice has been linked to increased resistance in bacterial infections in both human and veterinary healthcare,[1](#jvim15685-bib-0001){ref-type="ref"} and most especially in hospital practice.[2](#jvim15685-bib-0002){ref-type="ref"}, [3](#jvim15685-bib-0003){ref-type="ref"} Clinicians should apply principles of antimicrobial stewardship when considering their choice of antimicrobials,[4](#jvim15685-bib-0004){ref-type="ref"} which is not necessarily always the case currently in the United Kingdom (UK).[5](#jvim15685-bib-0005){ref-type="ref"} In some other European countries such as Sweden or Denmark, critically important antimicrobials have legally enforced restricted use in veterinary medicine.[6](#jvim15685-bib-0006){ref-type="ref"}

The British Equine Veterinary Association guidelines for responsible antimicrobial use advise that first‐line injectable antimicrobials should be a combination of procaine penicillin with gentamicin sulfate (P‐G) in most infectious scenarios encountered in equine practice (<http://www.beva.org.uk/protectme>). Among the PO antimicrobials available, a trimethoprim‐sulfadiazine (TMPS) combination is recommended for first‐line use[7](#jvim15685-bib-0007){ref-type="ref"} and is also the only licensed choice in horses in the UK.

Responsible use of antimicrobials is facilitated by in vitro antimicrobial susceptibility testing to inform antimicrobial choice. Breakpoints are determined based on the minimum inhibitory concentration (MIC) of an antimicrobial to separate isolates for which there is a high likelihood of treatment success (sensitive) versus those for which treatment is more likely to be ineffective (intermediate or resistant).[8](#jvim15685-bib-0008){ref-type="ref"}, [9](#jvim15685-bib-0009){ref-type="ref"} International groups including the Clinical and Laboratory Standards Institute (CLSI) and the European Union Committee on Antimicrobial Susceptibility Testing (EUCAST) have published suggested breakpoints for clinical application based on pharmacokinetics and pharmacodynamics to predict clinical efficacy.[10](#jvim15685-bib-0010){ref-type="ref"}, [11](#jvim15685-bib-0011){ref-type="ref"} However, very little specific data are available for horses, requiring some extrapolation from other species.[12](#jvim15685-bib-0012){ref-type="ref"}

Our aim was to examine the value of in vitro antimicrobial sensitivity testing in antimicrobial selection in both ambulatory and hospital practice. The prevalence of sensitivity to first‐line antimicrobials (parenteral P‐G and PO TMPS) was determined and subsequently the sensitivity to alternative antimicrobials was examined for the isolates found to be resistant to first‐line choices. The hypotheses were that bacteria cultured from a hospital population would have lower prevalence of in vitro sensitivity compared to ambulatory isolates as previously described[9](#jvim15685-bib-0009){ref-type="ref"} and that organisms resistant to P‐G or TMPS still could be treated successfully with noncritically important antimicrobials such as tetracyclines.

2. MATERIALS AND METHODS {#jvim15685-sec-0007}
========================

In this retrospective analysis, data were collected from all clinical samples submitted to The Liphook Equine Hospital Laboratory for culture and determination of antimicrobial sensitivity between January 2014 and December 2018.

Submitted samples were plated onto Columbia blood agar and MacConkey\'s agar, colistin‐nalidixic acid agar, or combinations thereof depending on sample type. Subcultures usually were prepared, depending on the purity of primary growth, to obtain pure cultures before suspending individual colonies in saline to a McFarlane standard of 0.5. The suspension then was processed using a VITEK 2 analyzer (BioMerieux, Basingstoke, Hampshire, UK) for bacterial identification. Isolates were further examined after separating Gram‐negative and Gram‐positive bacteria using a different array of antimicrobials to determine MICs (AST‐GN65, AST‐GP73, BioMerieux). Antimicrobial susceptibilities were examined across a range of dilutions from 0.5 to 16 μg/mL for gentamicin, 0.06 to 16 μg/mL for benzylpenicillin, 0.1 to 320 μg/mL for trimethoprim‐sulfamethoxazole (because sulfadiazine was not available for susceptibility testing on the analyzer used), 0.25 to 16 μg/mL for tetracycline, 0.25 to 8 μg/mL for ceftiofur, and 0.25 to 4 μg/mL for enrofloxacin. Antimicrobial breakpoints were selected from data provided by EUCAST and CLSI and used to categorize isolates as sensitive or resistant. For the purposes of analysis, isolates with MICs categorized as intermediate susceptibility were classified as resistant.[11](#jvim15685-bib-0011){ref-type="ref"}

All of the samples were categorized into different main anatomic sites of origin: skin/wounds (including fistulous withers, surgical incisions and IV catheters), respiratory (pleural fluid, bronchoalveolar lavage, tracheal wash, guttural pouch lavage, sinus fluid, nasal discharge), reproductive female (cervix, clitoris, fetus, uterus, vulvar or vaginal discharge), abscesses (including dental, foot or septic pedal bone), urinary (bladder biopsy, urine), ocular, other (surgical implants; internal biopsy samples such as intestines, liver, stomach, ovary, peritoneal fluid, synovial fluid, penile swab, mammary discharge, diarrhea), or unknown origin.

The population of isolates found to be resistant to P‐G was evaluated to determine the prevalence of sensitivity to other antimicrobials that might be selected as a second choice in practice consisting of TMPS, tetracycline, ceftiofur, and enrofloxacin. Not all isolates were tested against every antimicrobial, given that some would not be logical choices based on known pharmacodynamics. For example, gram‐negative bacteria were not tested for sensitivity to penicillin. Except for *Enterobacter spp*, *Enterococcus spp* was not tested for ceftiofur, and *Streptococcus spp* was not tested for enrofloxacin and gentamicin.[13](#jvim15685-bib-0013){ref-type="ref"}, [14](#jvim15685-bib-0014){ref-type="ref"}

The population of isolates found to be resistant to TMPS was evaluated to determine the prevalence of sensitivity to other antimicrobials that might be selected as a second choice in practice based on known pharmacodynamics comprising tetracycline, ceftiofur, enrofloxacin, or P‐G.

2.1. Statistical analysis {#jvim15685-sec-0008}
-------------------------

Bacterial resistance to antimicrobials was compared between samples derived from ambulatory practices and those obtained from the referral hospital by using a Chi‐squared test when appropriate (\>5 expected cases) or a Fisher\'s exact test, with a *P* value \<.05 indicating a significant difference.

The prevalences of resistance to the second‐choice antimicrobials in ambulatory and hospital practice also were compared with one another using a Chi‐squared test when appropriate (\>5 isolates) or a Fisher\'s exact test, with a *P* value \<.05 indicating a significant difference.

GraphPad Prism 8 software (GraphPad Prism version 8.0.0 for Windows, GraphPad Software, San Diego, California, <http://www.graphpad.com>) was used, with contingency tables to compare the data in ambulatory practice and in the referral hospital population, as well as second‐choice antimicrobials in pairs.

3. RESULTS {#jvim15685-sec-0009}
==========

A total of 6873 isolates were identified and their MICs determined during the study period. Of these, 6354 (92%) came from 345 different ambulatory practices and 519 (8%) came from a single referral hospital population.

3.1. Comparison of ambulatory and referral isolates {#jvim15685-sec-0010}
---------------------------------------------------

Overall 5685 (91%) of the 6354 ambulatory isolates were sensitive to P‐G (Table [1](#jvim15685-tbl-0001){ref-type="table"}), and 4833 (82%) were sensitive to TMPS (Table [2](#jvim15685-tbl-0002){ref-type="table"}). Of the 519 hospital isolates, 314 (64%) were sensitive to P‐G (Table [3](#jvim15685-tbl-0003){ref-type="table"}), and 275 (56%) were sensitive to TMPS (Table [4](#jvim15685-tbl-0004){ref-type="table"}).

###### 

Six thousand two‐hundred fifty isolates from 345 ambulatory practices and 491 isolates from a referral hospital tested for Penicillin‐Gentamicin (P‐G) sensitivity alongside prevalence of sensitivity (F, female)

  Penicillin‐Gentamicin   Total ambulatory   P‐G tested   P‐G sensitive   Total referral   P‐G tested   P‐G sensitive         
  ----------------------- ------------------ ------------ --------------- ---------------- ------------ --------------- ----- -----
  Skin/wounds             2151               2137         1915            89               291          271             135   50
  Respiratory             1267               1251         1148            92               108          106             88    83
  Reproductive F          330                305          280             92               5            5               5     100
  Abscesses               790                764          708             93               54           52              45    87
  Urinary                 242                220          207             94               11           8               4     50
  Ocular                  170                168          155             92               4            4               4     100
  Other                   324                319          300             94               34           33              24    73
  Unknown                 1094               1072         972             91               12           12              9     75
  Total                   6354               6250         5585            91               519          491             314   64

###### 

Five thousand nine‐hundred thirty isolates from 345 ambulatory practices and 489 isolates from a referral hospital tested for Trimethoprim‐Sulfamethoxazole (TMPS) sensitivity alongside prevalence of sensitivity (F, female)

  Trimethoprim‐sulfamethoxazole   Total ambulatory   TMPS tested   TMPS sensitive   Total referral   TMPS tested   TMPS sensitive         
  ------------------------------- ------------------ ------------- ---------------- ---------------- ------------- ---------------- ----- -----
  Skin/wounds                     2137               2001          1490             74               291           278              134   48
  Respiratory                     1267               1192          1035             87               108           99               74    75
  Reproductive F                  330                314           248              79               5             4                0     0
  Abscesses                       790                735           628              85               54            48               32    87
  Urinary                         242                216           167              77               11            11               0     0
  Ocular                          170                145           137              94               4             4                4     100
  Other                           324                287           244              85               34            34               23    68
  Unknown                         1094               1040          884              85               12            11               8     73
  Total                           6354               5930          4833             82               519           489              275   56

###### 

Six‐hundred sixty five ambulatory isolates found to be resistant to Penicillin‐Gentamicin (P‐G) and tested for sensitivity to alternative antimicrobials (F, female; TMPS, trimethoprim sulfamethoxazole combination)

  Ambulatory practice P‐G resistant   TMPS tested   TMPS sensitive   Tetra‐cycline tested   Tetracycline sensitive   Ceftio‐fur tested   Ceftiofur sensitive   Enro‐floxacin tested   Enrofloxacin sensitive                    
  ----------------------------------- ------------- ---------------- ---------------------- ------------------------ ------------------- --------------------- ---------------------- ------------------------ ---- ----- ----- ----
  Skin/wounds                         230           59               26                     234                      39                  17                    134                    61                       46   220   118   54
  Respiratory                         94            73               78                     101                      63                  62                    35                     18                       51   40    24    60
  Reproductive F                      22            11               50                     25                       7                   28                    16                     6                        38   18    14    78
  Abscesses                           51            25               49                     56                       22                  39                    29                     16                       55   44    26    59
  Urinary                             9             6                66                     13                       6                   46                    5                      1                        20   8     2     25
  Ocular                              10            5                50                     12                       6                   50                    3                      2                        67   8     4     50
  Other                               18            8                44                     16                       6                   38                    10                     6                        60   13    6     46
  Unknown                             95            51               54                     100                      47                  47                    37                     19                       51   52    34    65
  Total                               529           236              46                     557                      196                 35                    269                    129                      48   403   228   57

###### 

One thousand ninety seven ambulatory isolates found to be resistant to Trimethoprim‐sulfamethoxazole (TMPS) and tested for sensitivity to alternative antimicrobials (F, female; P‐G, Penicillin‐Gentamicin association)

  Ambulatory practice TMPS resistant   Tetra‐cycline tested   Tetracycline sensitive   Enro‐floxacin tested   Enrofloxacin sensitive   Ceftio‐fur tested   Ceftiofur sensitive   P‐G tested   P‐G sensitive                     
  ------------------------------------ ---------------------- ------------------------ ---------------------- ------------------------ ------------------- --------------------- ------------ --------------- ---- ------ ----- ----
  Skin/wounds                          515                    133                      26                     496                      301                 61                    366          227             62   506    301   60
  Respiratory                          150                    90                       60                     68                       40                  59                    114          90              79   158    125   79
  Reproductive F                       68                     34                       50                     58                       47                  81                    49           29              73   64     51    80
  Abscesses                            110                    35                       32                     92                       71                  77                    68           45              66   104    77    74
  Urinary                              50                     33                       66                     48                       30                  63                    24           20              83   43     40    93
  Ocular                               9                      5                        56                     9                        6                   67                    6            5               83   9      5     56
  Other                                44                     17                       39                     40                       29                  73                    31           20              65   41     30    73
  Unknown                              157                    63                       40                     108                      75                  69                    87           35              40   156    110   71
  Total                                1103                   410                      37                     919                      599                 65                    745          451             61   1081   739   68

Prevalence of resistance to P‐G was significantly different between ambulatory and referral isolates for all isolates combined (*P* \< .001) as well as for the subcategories of skin/wounds (*P* \< .001), respiratory (*P* \< .001), reproductive female (*P* \< .001), abscesses (*P* \< .001), ocular (*P* \< .001), other (*P* = .05), and unknown (*P* \< .001).

Prevalence of resistance to TMPS was significantly different between ambulatory and referral isolates for all isolates combined (*P* \< .001), as well as for the subcategories of skin/wounds (*P* = .003), respiratory (*P* \< .001), reproductive female (*P* = .01), urinary (*P* \< .001), ocular (*P* \< .001), other (*P* \< .001), and unknown (*P* \< .001).

3.2. Comparison of antimicrobials selected as second choice to resistant isolates {#jvim15685-sec-0011}
---------------------------------------------------------------------------------

The prevalence of sensitivity to the various second‐choice antimicrobials isolates found to be resistant to P‐G or TMPS are listed in Tables [3](#jvim15685-tbl-0003){ref-type="table"}, [4](#jvim15685-tbl-0004){ref-type="table"}, [5](#jvim15685-tbl-0005){ref-type="table"}, [6](#jvim15685-tbl-0006){ref-type="table"}. A significant difference (*P* \< .05) was found between the prevalence of resistance to each antimicrobial used when compared in pairs for all except TMPS and ceftiofur (*P* = .41), enrofloxacin and P‐G (*P* = .14), and ceftiofur and enrofloxacin (*P* = .59) for the ambulatory samples. A significant difference also was found between the rates of resistance to each antimicrobial used when compared in pairs for all except TMPS and tetracycline (*P* = .46), and ceftiofur and enrofloxacin (*P* = .38) for the hospital isolates.

###### 

One‐hundred seventy seven referral hospital isolates found to be resistant to Penicillin‐Gentamicin (P‐G) and tested for sensitivity to alternative antimicrobials (F, female; TMPS, trimethoprim sulfamethoxazole combination)

  Referral hospital P‐G resistant   TMPS tested   TMPS sensitive   Tetra‐cycline tested   Tetracycline sensitive   Ceftio‐fur tested   Ceftiofur sensitive   Enro‐floxacin tested   Enrofloxacin sensitive                   
  --------------------------------- ------------- ---------------- ---------------------- ------------------------ ------------------- --------------------- ---------------------- ------------------------ ---- ----- ---- ----
  Skin/wounds                       130           14               11                     136                      11                  8                     96                     31                       32   136   46   34
  Respiratory                       17            2                22                     18                       2                   11                    9                      4                        44   16    10   63
  Reproductive F                    0             0                0                      0                        0                   0                     0                      0                        0    0     0    0
  Abscesses                         6             2                33                     6                        1                   17                    3                      0                        0    7     3    43
  Urinary                           4             0                0                      4                        0                   0                     4                      0                        0    4     3    75
  Ocular                            0             0                0                      0                        0                   0                     0                      0                        0    0     0    0
  Other                             10            0                0                      10                       0                   0                     7                      0                        0    9     6    67
  Unknown                           2             0                0                      3                        0                   0                     1                      0                        0    3     2    67
  Total                             169           18               11                     177                      14                  8                     120                    35                       29   175   70   40

4. DISCUSSION {#jvim15685-sec-0012}
=============

We found that bacterial isolates collected from ambulatory practice were more likely to be sensitive to P‐G and to TMPS than those collected from a referral hospital. We also found that where resistance to first‐line antimicrobials was found, no second‐choice antimicrobial was consistently predicted to be efficacious, with \<68% of the isolates resistant to P‐G or TMPS being found to be sensitive to any other antimicrobial.

The finding of higher resistance rates in isolates from a referral hospital compared to those obtained from ambulatory practices (Tables [1](#jvim15685-tbl-0001){ref-type="table"}, [2](#jvim15685-tbl-0002){ref-type="table"}, [3](#jvim15685-tbl-0003){ref-type="table"}, [4](#jvim15685-tbl-0004){ref-type="table"}) also has been found in previous studies.[9](#jvim15685-bib-0009){ref-type="ref"}, [15](#jvim15685-bib-0015){ref-type="ref"} This observation probably can be explained because of higher antimicrobial exposure among a hospital bacterial population because resistance genes are put under more environmental pressure as well as other factors such as greater potential for transmission of resistant strains or resistance determinants among hospitalized horses and for stress to precipitate increased shedding of resistant strains.[2](#jvim15685-bib-0002){ref-type="ref"} It is especially important to establish MICs for isolates from within a hospital population because of a generally lower likelihood of antimicrobial efficacy. By the same reasoning, it is logical that we found protected antimicrobials such as enrofloxacin and ceftiofur to have a lower prevalence of resistance among isolates because they are used less commonly (Tables [5](#jvim15685-tbl-0005){ref-type="table"}‐8). This latter finding might be used incorrectly as justification to employ these antimicrobials more frequently as first‐line choices for bacterial infections although the inevitable consequence of such action would be to rapidly increase resistance prevalence to these antimicrobials, leaving little choice thereafter.

The array of second‐line antimicrobials was selected based on common equine clinical practice and also availability of these drugs in the UK. Enrofloxacin and doxycycline however are not licensed for use in horses in the UK, and ceftiofur is only licensed for bacterial respiratory diseases associated with *Streptococcus spp*, *Staphylococcus spp*, and *Pasteurella spp*. Therefore, when second‐line antimicrobials are to be selected, preference should be given licensed choices such as oxytetracycline, P‐G, and TMPS, which have been shown to have adequately low MICs. Ceftiofur might be a reasonable choice in the case of isolates found to be resistant to oxytetracycline, P‐G, and TMPS, especially in the case of respiratory disease. Doxycycline might be reasonably selected as a second‐line antimicrobial when P‐G and TMPS resistance is found, when for reasons of practicality or safety parenteral antimicrobial administration is considered unsuitable or both. Enrofloxacin should be conserved on both legal and medical grounds and should only be used when none of the aforementioned antimicrobials is considered suitable based on MIC data. Enrofloxacin has a relatively limited expected spectrum of activity and is not a reasonable choice for most anerobic or streptococcal infections.[13](#jvim15685-bib-0013){ref-type="ref"}, [14](#jvim15685-bib-0014){ref-type="ref"}

In ambulatory cases where MIC data predicted likely failure of P‐G treatment, the predicted success of second‐choice antimicrobials varied from 35% for tetracyclines to 57% for enrofloxacin, whereas for hospital isolates the equivalent figures were 8% for tetracyclines to 40% for enrofloxacin (Tables [5](#jvim15685-tbl-0005){ref-type="table"} and 7). In ambulatory cases where MIC data predicted likely failure of TMPS treatment, the predicted success of second choice antimicrobials varied from 37% for tetracycline to 68% for P‐G, whereas for hospital isolates the equivalent figures were 23% for tetracyclines to 55% for enrofloxacin (Tables [6](#jvim15685-tbl-0006){ref-type="table"} and 8). In ambulatory practice, there may be greater indication for PO antimicrobials for reasons of practicality and therefore preferences for TMPS, doxycycline, or enrofloxacin. Although enrofloxacin showed lower rates of resistance among the isolates from ambulatory cases compared to the other PO drugs, the rates of resistance nevertheless were high enough to prevent any confidence that enrofloxacin would be efficacious in the absence of determining MIC data. Also, enrofloxacin is not licensed for use in horses, is firmly within the group of critically important antimicrobials, and therefore should be used only with very good evidence‐based reasoning. For hospital referral practice, parenteral administration is rarely problematic, meaning that parenteral P‐G frequently is used as a first‐line choice, and parenteral TMPS or oxytetracycline could be suitable second‐choice antimicrobials where resistance is seen to P‐G. Although sensitivity rates of P‐G‐resistant isolates generally were quite poor to TMPS and tetracyclines (11 and 8%, respectively, Table 7), these drugs nonetheless should be selected when the MIC is found to be below the clinical breakpoints or when other circumstances exist that might promote efficacy of these drugs (eg, local application). Although where resistance is seen to P‐G, TMPS, and oxytetracycline, the further choices of ceftiofur or enrofloxacin might be considered, the sensitivity rates of isolates to these 2 further protected antimicrobials were only 29 and 40%, respectively, reinforcing the fact that they would be poor speculative choices and only should be used based on MIC data.

###### 

Two‐hundred fourteen referral hospital isolates found to be resistant to Trimethoprim‐sulfamethoxazole (TMPS) and tested for sensitivity to alternative antimicrobials (F, female; P‐G, Penicillin‐Gentamicin association)

  Referral hospital TMPS resistant   Tetra‐cycline tested   Tetracycline sensitive   Enro‐floxacin tested   Enrofloxacin sensitive   Ceftio‐fur tested   Ceftiofur sensitive   P‐G tested   P‐G sensitive                    
  ---------------------------------- ---------------------- ------------------------ ---------------------- ------------------------ ------------------- --------------------- ------------ --------------- ----- ----- ---- ----
  Skin/wounds                        143                    28                       20                     139                      69                  50                    84           38              45    141   41   29
  Respiratory                        24                     5                        21                     23                       14                  61                    17           9               53    25    13   52
  Reproductive F                     0                      0                        0                      0                        0                   0                     0            0               0     0     0    0
  Abscesses                          16                     8                        50                     15                       10                  67                    12           7               58    15    9    60
  Urinary                            12                     6                        50                     12                       6                   50                    10           2               20    10    2    20
  Ocular                             0                      0                        0                      0                        0                   0                     0            0               0     0     0    0
  Other                              11                     2                        18                     11                       9                   82                    16           12              75    11    1    9
  Unknown                            3                      0                        0                      2                        1                   50                    1            1               100   3     1    33
  Total                              209                    49                       23                     202                      110                 55                    140          69              49    205   67   33

Strict application of MIC data to predict clinical efficacy or inefficacy sometimes may mislead because the many assumptions underlying the prediction of sensitivity and resistance might not always be correct. The so‐called 60‐90 rule often is quoted as a guide, which states that bacterial infections with in vitro prediction of efficacy to a particular antimicrobial will resolve in 90% of patients treated with that antimicrobial, whereas 60% of bacterial isolates with predicted resistance still might respond well.[16](#jvim15685-bib-0016){ref-type="ref"} There are many instances and reasons why bacteria with apparent in vitro resistance to an antimicrobial actually might respond well clinically to that antimicrobial. These factors include the host\'s own immunity, which contributes to bacterial clearance, but also pharmacokinetic properties that might favor antimicrobial accumulation at a particular site of infection. For example, urinary excretion of TMPS and P‐G will lead to especially high urinary concentrations and clinical efficacy against urinary tract isolates even when in vitro testing might suggest resistance.[17](#jvim15685-bib-0017){ref-type="ref"}, [18](#jvim15685-bib-0018){ref-type="ref"} This divergence between in vitro test results and clinical efficacy is likely to be even more pronounced for infections that are amenable to topical or local treatments (eg, intra‐ocular, intra‐uterine, dermal, IV regional perfusion) because local concentrations will be many times higher than could be achieved by systemic administration. For example, an isolate with an MIC for gentamicin of 16 μg/mL would be predicted to be highly resistant based on efficacy requiring attainment of 128 to 160 μg/mL gentamicin (8‐10 times the MIC) in the locality of the infection, which is unachievable with systemic administration.[9](#jvim15685-bib-0009){ref-type="ref"} However, such local concentrations are relatively easily achievable by topical treatment.[19](#jvim15685-bib-0019){ref-type="ref"} Local treatments also will decrease the incidence of adverse effects on the fecal microbiota and the development of antimicrobial‐associated diarrhea.[20](#jvim15685-bib-0020){ref-type="ref"} Another important consideration is the synergistic action of some antimicrobial combinations leading to better clinical efficacy than would be expected based on the spectrum of each antimicrobial taken separately.[21](#jvim15685-bib-0021){ref-type="ref"} For example, trimethoprim and penicillin demonstrate synergism when given along with aminoglycosides.[22](#jvim15685-bib-0022){ref-type="ref"}

Conversely, there are instances and reasons why bacteria with apparent in vitro sensitivity to an antimicrobial may not respond well clinically to that antimicrobial. Infections may occur at sites poorly accessible to the chosen antimicrobial or potentially antagonistic factors may impair the pharmacodynamic properties of the antimicrobial in question.[23](#jvim15685-bib-0023){ref-type="ref"}, [24](#jvim15685-bib-0024){ref-type="ref"}, [25](#jvim15685-bib-0025){ref-type="ref"} Additionally, suppressive or antagonistic drug interactions can occur when poorly selected polypharmacy is employed.[26](#jvim15685-bib-0026){ref-type="ref"} A further intriguing strategy for improving antimicrobial sensitivity involves the concept of collateral drug sensitivity where a bacterial strain that has acquired resistance to 1 class of antimicrobials (especially aminoglycosides) may sometimes simultaneously become more sensitive to other antimicrobials.[27](#jvim15685-bib-0027){ref-type="ref"}, [28](#jvim15685-bib-0028){ref-type="ref"}, [29](#jvim15685-bib-0029){ref-type="ref"}

Prudent use of antimicrobials hopefully will promote good efficacy in clearing bacterial infections while limiting the increase in bacterial resistance.[30](#jvim15685-bib-0030){ref-type="ref"} Many facets contribute to achieving this balance beginning with correct identification of the specific pathogenic threats, and followed by careful selection of appropriate antimicrobials, which requires awareness of their pharmacokinetic and pharmacodynamic properties as well as their MICs for specific pathogens. Prioritization of nonprotected antimicrobials always should be practiced where supported by the considerations discussed above, thus conserving additional antimicrobials for clinical situations for which no other choices exist. Selection of antimicrobials in the absence of supportive data increases the risk of inefficacy along with subtherapeutic exposure, which contributes to the prevalence of resistance. When budgetary constraints dictate speculative selection, there is rarely any justification for the use of protected antimicrobials.

Our study reconfirmed previous evidence of higher rates of antimicrobial resistance in isolates from an equine hospital compared to ambulatory practices. Additionally, we found that when resistance was found to first‐line antimicrobial choices, the choice of subsequent antimicrobials could not be predicted with confidence and always should be based on MIC data rather than speculation.
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